New Treatment Option for Acromegaly: Debate and Discussion on the Use of Oral Octreotide

Saturday, April 2, 2016 | 6:30 – 9:30 PM EST
Westin Boston Waterfront Hotel, Grand Ballroom

This course is a live CME-certified ancillary symposium presented at ENDO 2016, the Endocrine Society's 98th Annual Meeting and Expo, held in Boston, Massachusetts, April 1–4, 2016. ENDO 2016 ancillary symposia are developed through the Endocrine Society’s Special Programs Committee (SPC). There is no cost to attend, and all ENDO 2016 attendees are welcome; however, seating is limited and advance registration is recommended. You must be registered for ENDO 2016 to attend an ENDO 2016 ancillary symposium.

This activity is supported by an educational grant from Chiasma Inc.

SYMPOSIUM AGENDA

Opening and Welcome
Program Director: Anne Klibanski,MD – Massachusetss General Hospital

Overview of Current Treatment Options
Anne Klibanski, MD – Massachusetts General Hospital

The Case for Oral Octreotide in Acromegaly
Shlomo Melmed, MD – Cedars-Sinai Health System

The Case Against Oral Octreotide in Acromegaly
Peter Trainer, MD – The Christie NHS Foundation Trust

Panel Discussion and Audience Questions

Target Audience

This continuing medical education activity should be of substantial interest to endocrinologists, neurosurgeons and allied healthcare providers treating patients with acromegaly.

Learning Objectives

Upon completion of this educational activity, learners will be better able to:

  • Explain efficacy and safety outcomes associated with use of different treatment options, including control of GH/IGF-I levels, amelioration of signs and symptoms, improved QoL, ease of therapy administration.
  • Educate patients in successful management of their disease given the complexities of everyday life.
  • Understand and share latest clinical developments in treating patients with acromegaly.

Additional Information

Target Audience: 
Physician-in-practice
Fellow
Resident
Clinical researcher
Scientific researcher
Educator/Teacher
Pharmacist
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Other
Competency Area: 
Patient Care and Procedural Skills
Medical Knowledge
Topic Area: 
Adrenal/HPA Axis
Quality Improvement and Healthcare Delivery
General Endocrinology
Neuroendocrinology and Pituitary
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Level 4 (Learning: Competence (Shows How))
Level 5 (Performance (Does))
Activity summary
Available credit: 
  • 2.50 AMA PRA Category 1 Credits
  • 2.50 CME Certificate of Participation
Course opens: 
04/02/2016
Course expires: 
04/02/2017
Rating: 
0
Boston, MA 02210
United States

Anne Klibanski, MD - Program Director
Chief, Neuroendocrine
Director, Neuroendocrine and Pituitary Tumor Clinical Center
Massachusetts General Hospital
Boston, Massachusetts

Shlomo Melmed, MD
Executive Vice President and Dean of the Medical Faculty
Cedars-Sinai Health System
Los Angeles, California

Peter Trainer, BSc, MB, ChB, MD, FRCP
Consultant Endocrinologist
The Christie NHS Foundation Trust
Manchester, United Kingdom

DISCLOSURE POLICY

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:
Shlomo Melmed, MD: Ad Hoc Consultant, Novartis, Consultant, ISIS; Coinvestigator, Ipsen; Investigator, Pfizer, Inc.; Scientific Board Member, Chiasma
Peter Trainer, MD: Advisory Board Member, Chiasma; Principal Investigator, Antisense Therapeutics, Chiasma, Ipsen

The following faculty reported no relevant financial relationship(s): Anne Klibanski, MD

The following SPC member who planned and reviewed content for this activity reported no relevant financial relationships:
Lisa Nachtigall, MD: Consultant, Genentech; Consultant and Principal Investigator, Ipsen

The following SPC Committee members reported relevant financial relationships:
Zahid Ahmad, MD: Consultant, Regeneron; Speaker, Amgen, Genzyme
Sarah Berga, MD: Advisory Board, Agile Therapeutics, Noven Pharmaceuticals, Inc., Watson Pharmaceuticals, Teva Pharmaceuticals Industries, Shionogi, Inc.; Consultant, AHC Media, LLC, Shionogi, Inc.
Paresh Dandona, MD, PhD, FRCP: Consultant and Speaker, AstraZeneca, Bristol Myers Squibb, Janssen, Merck, Novo Nordisk
Irl Hirsch, MD: Consultant, Abbott Laboratories, Johnson & Johnson, Roche Diagnostics, Valeritas; Investigator, Sanofi
E Michael Lewiecki, MD: Consultant, Amgen, Eli Lilly, Merck, Radius Health, AgNovos Healthcare, Theranova; Research Grant Support, Amgen, Eli Lilly, Merck
Amy Rothberg, MD: Consultant, Novo Nordisk; Speaker, Takeda Pharmaceuticals
Guillermo E Umpierrez, MD, CDE: Advisory Board and Consultant, Abbott, Boehringer Ingelheim, Merck, Novo Nordisk, Regeneron, Sanofi; Research Grant Support, Boehringer Ingelheim, Merck & Co., Novo Nordisk, Regeneron

The following SPC members reported no relevant financial relationships: John Carmichael, MD; Natalie Cusano, MD; Alan Kelly, MD; Larry Fox, MD; Michael S Irwig, MD; Connie B Newman, MD

Endocrine Society and CMM Global staff associated with the development of content for this activity reported no relevant financial relationships.

Available Credit

  • 2.50 AMA PRA Category 1 Credits
  • 2.50 CME Certificate of Participation

Accreditation Period

Course opens: 
04/02/2016
Course expires: 
04/02/2017